• +1-646-491-9876
    • +91-20-67278686

    Search

    Osteosarcoma - Pipeline Review, H1 2017

    Osteosarcoma - Pipeline Review, H1 2017

    • Report Code ID: RW0001709469
    • Category Pharmaceuticals
    • No. of Pages 255
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Osteosarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

    Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 7, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 4 molecules, respectively.

    Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Osteosarcoma - Overview 7
    Osteosarcoma - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 15
    Osteosarcoma - Therapeutics Assessment 16
    Assessment by Target 16
    Assessment by Mechanism of Action 19
    Assessment by Route of Administration 22
    Assessment by Molecule Type 24
    Osteosarcoma - Companies Involved in Therapeutics Development 26
    Advaxis Inc 26
    Allosteros Therapeutics Inc 26
    Amgen Inc 27
    AVEO Pharmaceuticals Inc 27
    Bayer AG 28
    Bellicum Pharmaceuticals Inc 28
    Bristol-Myers Squibb Company 29
    Celldex Therapeutics Inc 29
    CorMedix Inc 30
    CytRx Corp 30
    Eisai Co Ltd 31
    Eleison Pharmaceuticals LLC 31
    Intezyne Technologies Inc 32
    Isofol Medical AB 32
    Johnson & Johnson 33
    MacroGenics Inc 33
    MD Biosciences GmbH 34
    MediaPharma srl 34
    Merck & Co Inc 35
    Merck KGaA 35
    Merrimack Pharmaceuticals Inc 36
    Novartis AG 36
    Oncolys BioPharma Inc 37
    Pfizer Inc 37
    Shionogi & Co Ltd 38
    Teijin Pharma Ltd 38
    United Therapeutics Corp 39
    Osteosarcoma - Drug Profiles 40
    3D-QM - Drug Profile 40
    3D-QMS - Drug Profile 41
    ADXS-HER2 - Drug Profile 42
    aldoxorubicin hydrochloride - Drug Profile 46
    AM-7209 - Drug Profile 63
    AU-101 - Drug Profile 64
    AV-203 - Drug Profile 65
    avelumab - Drug Profile 68
    axitinib - Drug Profile 77
    Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 83
    Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 85
    Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 86
    Celyvir - Drug Profile 87
    cisplatin SR - Drug Profile 88
    daunorubicin hydrochloride - Drug Profile 90
    dihydroartemisinin - Drug Profile 91
    dinutuximab - Drug Profile 92
    enoblituzumab - Drug Profile 94
    everolimus - Drug Profile 97
    glembatumumab vedotin - Drug Profile 111
    ipilimumab + nivolumab - Drug Profile 116
    irinotecan hydrochloride - Drug Profile 120
    IT-139 - Drug Profile 132
    JNJ-64457107 - Drug Profile 134
    lenvatinib mesylate - Drug Profile 136
    ligerin - Drug Profile 149
    MD-401A - Drug Profile 150
    Modufolin - Drug Profile 151
    Monoclonal Antibody for Osteosarcoma - Drug Profile 153
    Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 154
    Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 155
    MPE-8.3 - Drug Profile 157
    NT-157 - Drug Profile 158
    OBP-702 - Drug Profile 160
    Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 161
    pazopanib hydrochloride - Drug Profile 162
    pembrolizumab - Drug Profile 171
    Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 219
    radium Ra 223 dichloride - Drug Profile 221
    RSF-101 - Drug Profile 230
    S-588410 - Drug Profile 232
    SEN-461 - Drug Profile 234
    Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 235
    Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 236
    taurolidine - Drug Profile 237
    Vaccine for Osteosarcoma - Drug Profile 238
    VIMO-001 - Drug Profile 239
    Osteosarcoma - Dormant Projects 240
    Osteosarcoma - Discontinued Products 241
    Osteosarcoma - Product Development Milestones 242
    Featured News & Press Releases 242
    Appendix 250
    Methodology 250
    Coverage 250
    Secondary Research 250
    Primary Research 250
    Expert Panel Validation 250
    Contact Us 250
    Disclaimer 251

    List of Tables

    Number of Products under Development for Osteosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Osteosarcoma - Pipeline by Advaxis Inc, H1 2017
    Osteosarcoma - Pipeline by Allosteros Therapeutics Inc, H1 2017
    Osteosarcoma - Pipeline by Amgen Inc, H1 2017
    Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Osteosarcoma - Pipeline by Bayer AG, H1 2017
    Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
    Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H1 2017
    Osteosarcoma - Pipeline by CorMedix Inc, H1 2017
    Osteosarcoma - Pipeline by CytRx Corp, H1 2017
    Osteosarcoma - Pipeline by Eisai Co Ltd, H1 2017
    Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1 2017
    Osteosarcoma - Pipeline by Intezyne Technologies Inc, H1 2017
    Osteosarcoma - Pipeline by Isofol Medical AB, H1 2017
    Osteosarcoma - Pipeline by Johnson & Johnson, H1 2017
    Osteosarcoma - Pipeline by MacroGenics Inc, H1 2017
    Osteosarcoma - Pipeline by MD Biosciences GmbH, H1 2017
    Osteosarcoma - Pipeline by MediaPharma srl, H1 2017
    Osteosarcoma - Pipeline by Merck & Co Inc, H1 2017
    Osteosarcoma - Pipeline by Merck KGaA, H1 2017
    Osteosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
    Osteosarcoma - Pipeline by Novartis AG, H1 2017
    Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H1 2017
    Osteosarcoma - Pipeline by Pfizer Inc, H1 2017
    Osteosarcoma - Pipeline by Shionogi & Co Ltd, H1 2017
    Osteosarcoma - Pipeline by Teijin Pharma Ltd, H1 2017
    Osteosarcoma - Pipeline by United Therapeutics Corp, H1 2017
    Osteosarcoma - Dormant Projects, H1 2017
    Osteosarcoma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Osteosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advaxis Inc
    Allosteros Therapeutics Inc
    Amgen Inc
    AVEO Pharmaceuticals Inc
    Bayer AG
    Bellicum Pharmaceuticals Inc
    Bristol-Myers Squibb Company
    Celldex Therapeutics Inc
    CorMedix Inc
    CytRx Corp
    Eisai Co Ltd
    Eleison Pharmaceuticals LLC
    Intezyne Technologies Inc
    Isofol Medical AB
    Johnson & Johnson
    MacroGenics Inc
    MD Biosciences GmbH
    MediaPharma srl
    Merck & Co Inc
    Merck KGaA
    Merrimack Pharmaceuticals Inc
    Novartis AG
    Oncolys BioPharma Inc
    Pfizer Inc
    Shionogi & Co Ltd
    Teijin Pharma Ltd
    United Therapeutics Corp

    Request for Sample

    Report Url http://www.reportsweb.com//osteosarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//osteosarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//osteosarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments